Biopharmaceuticals, an Industrial Perspective

Contributors. Acknowledgements. Preface. Biopharmaceuticals, an overview; G. Walsh. Abciximab: The First Platelet Glycoprotein IIb/IIIa Receptor Antagonist; R.E. Jordan, et al. Recombinant Coagulation Factor IX (BeneFix®); J. Edwards, N. Kirby. Biopharmaceutical Drug Development: A Case History; M. Foote, T. Boone. Follitropin beta (Puregon); H.J. Out. Insulin Lispro (Humalog); R.E. Chance, et al. Interferon beta-1b - the first long-term effective treatment of relapsing-remitting and secondary progressive multiple sclerosis (MS); R. Horowski, et al. Reteplase, a recombinant Plasminogen activator; M. Waller, U. Kohnert. Stabilisation of biopharmaceutical products and finished product formulations; M.S. Hora, B.-L. Chen. Patent Law for Biopharmaceuticals; R.S. Crespi. The development of new medicines: an overview; J.C. Stinson. The EMEA and regulatory control of (bio)pharmaceuticals within the European Union; G. Walsh. Biopharmaceutical Validation: an overview; S. Slater. Validation of Biopharmaceutical Chromatography Systems; K.F. Williams, C.J.A. Davids. Validation of Water for Injections (WFI) for Biopharmaceutical Manufacture; P. Baker, W. Allan. Information retrieval and the biopharmaceutical industry: an introductory overview; P. O'Donnell. Information technology and the internet as a resource of biopharmaceutical information; J.P. Jenuth, et al. Marketing Issues for the (Bio)pharmaceutical sector; S. Spinka. Viral mediated gene therapy; B. Murphy. Pharmaceutical gene medicines for non-viral gene therapy; A. Rolland, et al. Index.